BG64126B1 - Заместени бензиламинопиперидини - Google Patents

Заместени бензиламинопиперидини Download PDF

Info

Publication number
BG64126B1
BG64126B1 BG102288A BG10228898A BG64126B1 BG 64126 B1 BG64126 B1 BG 64126B1 BG 102288 A BG102288 A BG 102288A BG 10228898 A BG10228898 A BG 10228898A BG 64126 B1 BG64126 B1 BG 64126B1
Authority
BG
Bulgaria
Prior art keywords
compound
halogen
trifluoromethyl
methoxy
phenylpiperidine
Prior art date
Application number
BG102288A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG102288A (en
Inventor
Kunio Satake
Yuji Shishido
Hiroaki Wakabayashi
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG102288A publication Critical patent/BG102288A/xx
Publication of BG64126B1 publication Critical patent/BG64126B1/bg

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BG102288A 1995-08-24 1998-02-27 Заместени бензиламинопиперидини BG64126B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB9500683 1995-08-24
PCT/IB1996/000572 WO1997008144A1 (en) 1995-08-24 1996-06-10 Substituted benzylaminopiperidine compounds

Publications (2)

Publication Number Publication Date
BG102288A BG102288A (en) 1998-09-30
BG64126B1 true BG64126B1 (bg) 2004-01-30

Family

ID=11004362

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102288A BG64126B1 (bg) 1995-08-24 1998-02-27 Заместени бензиламинопиперидини

Country Status (42)

Country Link
US (1) US6506775B1 (es)
EP (2) EP0861235B1 (es)
JP (1) JP3084069B2 (es)
KR (1) KR100288673B1 (es)
CN (1) CN1153764C (es)
AP (1) AP643A (es)
AR (1) AR006305A1 (es)
AT (2) ATE258166T1 (es)
AU (1) AU702698B2 (es)
BG (1) BG64126B1 (es)
BR (1) BR9609989A (es)
CA (1) CA2227814C (es)
CO (1) CO4480738A1 (es)
CZ (1) CZ297543B6 (es)
DE (2) DE69631390T2 (es)
DK (2) DK1114817T3 (es)
DZ (1) DZ2086A1 (es)
ES (2) ES2163017T3 (es)
HK (1) HK1014935A1 (es)
HR (1) HRP960386B1 (es)
HU (1) HU225480B1 (es)
IL (1) IL119078A (es)
IS (1) IS1947B (es)
MA (1) MA23961A1 (es)
MX (1) MX9801467A (es)
MY (1) MY114800A (es)
NO (1) NO310720B1 (es)
NZ (1) NZ308207A (es)
OA (1) OA10666A (es)
PE (2) PE1398A1 (es)
PL (1) PL186773B1 (es)
PT (2) PT1114817E (es)
RO (1) RO119299B1 (es)
RU (1) RU2152930C2 (es)
SI (2) SI1114817T1 (es)
SK (1) SK282925B6 (es)
TN (1) TNSN96107A1 (es)
TR (1) TR199800300T1 (es)
TW (1) TW340842B (es)
UA (1) UA48981C2 (es)
WO (1) WO1997008144A1 (es)
YU (1) YU49122B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9706196A (es) * 1996-08-14 1998-02-28 Pfizer Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p.
TW426667B (en) * 1997-11-19 2001-03-21 Pfizer Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists
US6777428B1 (en) 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
DE60007625T2 (de) * 1999-05-06 2004-11-18 Pfizer Products Inc., Groton Substituierte benzolactamverbindungen
RS49964B (sr) 1999-05-17 2008-09-29 Pfizer Products Inc., Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli
AP1396A (en) 1999-05-21 2005-04-19 Pfizer Prod Inc 1-Trifluoromethyl-4-hydroxy-7-piperidinylaminomethylchroman derivatives.
JP2001172178A (ja) * 1999-10-25 2001-06-26 Pfizer Prod Inc 偏頭痛治療用のnk−1レセプターアンタゴニスト及びエレトリプタン
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (en) * 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
US6911544B2 (en) 2002-10-23 2005-06-28 Pfizer Inc. Process for the preparation of (S,S)-cis-2-phenyl-3-aminopiperidine
US7608629B2 (en) 2003-04-18 2009-10-27 Eli Lilly And Company (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-HT1F agonists
CA2566920A1 (en) * 2004-05-21 2005-12-01 Pfizer Products Inc. Metabolites of (+)-(2s, 3s)-3-(2-methoxy-5-trifluoromethoxybenzylamino)-2-phenyl-piperidine
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
CN101495184A (zh) 2005-07-15 2009-07-29 Amr科技公司 芳基和杂芳基取代的四氢苯并氮杂及其在阻断去甲肾上腺素多巴胺和血清素的重摄取中的应用
RU2008116844A (ru) 2005-09-29 2009-11-10 Мерк энд Ко., Инк. (US) Ацилированные производные спиропиперидина как модуляторы рецептора меланокортина-4
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2946778A1 (en) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EA016079B1 (ru) 2007-01-10 2012-01-30 Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
KR20100126467A (ko) 2008-03-03 2010-12-01 타이거 파마테크 티로신 키나아제 억제제
JP5511080B2 (ja) 2008-03-31 2014-06-04 興和株式会社 1,3−ジヒドロイソベンゾフラン誘導体
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
CN102458123A (zh) 2009-05-12 2012-05-16 阿尔巴尼分子研究公司 芳基、杂芳基和杂环取代的四氢异喹啉及其用途
PE20120373A1 (es) 2009-05-12 2012-05-17 Albany Molecular Res Inc 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina
KR20120023072A (ko) 2009-05-12 2012-03-12 브리스톨-마이어스 스큅 컴퍼니 (S)-7-(〔1,2,4〕트리아졸〔1,5-a〕피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린의 결정형 및 이의 용도
BR112012008849A2 (pt) 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
EP3330377A1 (en) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
US9029341B2 (en) 2010-08-17 2015-05-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
JP2014514321A (ja) 2011-04-21 2014-06-19 メルク・シャープ・アンド・ドーム・コーポレーション インスリン様増殖因子1受容体阻害剤
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Erk阻害剤である新規化合物
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
CN105073746B (zh) 2012-12-20 2017-03-22 默沙东公司 作为hdm2抑制剂的取代的咪唑并吡啶
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
EP3833668A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
US5364943A (en) * 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
JPH0794440B2 (ja) * 1991-03-26 1995-10-11 フアイザー・インコーポレイテツド 置換ピペリジンの立体選択的製造
JPH07110850B2 (ja) * 1991-06-20 1995-11-29 フアイザー・インコーポレイテツド 窒素含有複素環化合物のフルオロアルコキシベンジルアミノ誘導体
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0653208A3 (en) * 1993-11-17 1995-10-11 Pfizer Substance P antagonists for the treatment or prevention of sunburn.
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
DK0780375T3 (da) * 1995-12-21 2002-10-07 Pfizer 3-((5-substitueret benzyl)amino)-2-phenylpiperidiner som substans P-antagonister
US5990125A (en) 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer

Also Published As

Publication number Publication date
AP9600850A0 (en) 1996-10-31
TR199800300T1 (xx) 1998-06-22
SK282925B6 (sk) 2003-01-09
MA23961A1 (fr) 1997-04-01
DE69616817T2 (de) 2002-04-04
HRP960386A2 (en) 1998-04-30
DE69631390D1 (de) 2004-02-26
HU225480B1 (en) 2006-12-28
TW340842B (en) 1998-09-21
PL186773B1 (pl) 2004-02-27
JPH10510554A (ja) 1998-10-13
PL325332A1 (en) 1998-07-20
BR9609989A (pt) 1999-07-06
CZ52198A3 (cs) 1999-01-13
ATE208377T1 (de) 2001-11-15
ATE258166T1 (de) 2004-02-15
PE20010700A1 (es) 2001-07-09
AR006305A1 (es) 1999-08-25
DZ2086A1 (fr) 2002-07-22
PT861235E (pt) 2002-03-28
DE69631390T2 (de) 2004-11-25
NO980751L (no) 1998-02-23
DK1114817T3 (da) 2004-04-26
CZ297543B6 (cs) 2007-02-07
KR19990044077A (ko) 1999-06-25
RO119299B1 (ro) 2004-07-30
AP643A (en) 1998-04-24
HUP9901159A3 (en) 2000-05-29
NO980751D0 (no) 1998-02-23
YU47896A (sh) 1998-12-23
IL119078A0 (en) 1996-11-14
AU5776996A (en) 1997-03-19
SI1114817T1 (en) 2004-06-30
AU702698B2 (en) 1999-03-04
CA2227814A1 (en) 1997-03-06
CO4480738A1 (es) 1997-07-09
CA2227814C (en) 2002-12-31
UA48981C2 (uk) 2002-09-16
EP0861235A1 (en) 1998-09-02
TNSN96107A1 (fr) 2005-03-15
HRP960386B1 (en) 2002-04-30
US6506775B1 (en) 2003-01-14
CN1153764C (zh) 2004-06-16
BG102288A (en) 1998-09-30
MY114800A (en) 2003-01-31
SK20798A3 (en) 1999-03-12
IS4644A (is) 1997-12-30
DK0861235T3 (da) 2001-12-27
SI0861235T1 (en) 2002-04-30
OA10666A (en) 2002-11-25
WO1997008144A1 (en) 1997-03-06
EP1114817A1 (en) 2001-07-11
NO310720B1 (no) 2001-08-20
EP1114817B1 (en) 2004-01-21
HK1014935A1 (en) 1999-10-08
ES2211684T3 (es) 2004-07-16
IS1947B (is) 2004-10-13
PT1114817E (pt) 2004-05-31
ES2163017T3 (es) 2002-01-16
PE1398A1 (es) 1998-02-27
IL119078A (en) 2003-11-23
YU49122B (sh) 2004-03-12
JP3084069B2 (ja) 2000-09-04
CN1193961A (zh) 1998-09-23
EP0861235B1 (en) 2001-11-07
MX9801467A (es) 1998-05-31
KR100288673B1 (ko) 2001-05-02
NZ308207A (en) 1998-07-28
HUP9901159A2 (hu) 1999-07-28
DE69616817D1 (de) 2001-12-13
RU2152930C2 (ru) 2000-07-20

Similar Documents

Publication Publication Date Title
BG64126B1 (bg) Заместени бензиламинопиперидини
EP0699199B1 (en) Heteroatom substituted alkyl benzylaminoquinuclidines as substance p antagonists
FI114637B (fi) Menetelmä terapeuttisesti käytettävien substituoitujen kinuklidiinien valmistamiseksi
JP2535134B2 (ja) 縮合三環式窒素含有複素環
US5744480A (en) Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
CA2309434A1 (en) New 4-arylpiperidine derivatives for the treatment of pruritus
UA59417C2 (uk) Сполуки піперидиніламінометильних трифлуорометильних циклічних етерів, фармацевтична композиція (варіанти) та спосіб лікування (варіанти)
US5789423A (en) 3- 5-substituted benzyl)amino!-2-phenylpiperidines as substance P antagonists
US6329396B1 (en) Substituted benzylaminopiperidine compounds
AU610492B2 (en) 5-substituted octahydroindolizine analgesics compounds and 7-keto intermediates
BG64623B1 (bg) Нови морфолинови производни, метод за тяхното получаване и фармацевтични състави, които ги съдържат
JP3172461B2 (ja) サブスタンスpアンタゴニストとしての3−[(5−置換ベンジル)アミノ]−2−フェニルピペリジン
US6083943A (en) Substituted azaheterocyclecarboxylic acid
JP2822274B2 (ja) P物質拮抗剤としてのヘテロ原子置換アルキルベンジルアミノキヌクリジン類